Fennec Pharmaceuticals
FENC
55 hedge funds and large institutions have $108M invested in Fennec Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 4 closing their positions.
266% more call options, than puts
Call options by funds: $458K | Put options by funds: $125K
6% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 16
0.55% more ownership
Funds ownership: 53.34% → 53.88% (+0.55%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2% less funds holding
Funds holding: 56 → 55 (-1)
14% less capital invested
Capital invested by funds: $125M → $108M (-$16.9M)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Solas Capital Management
Darien,
Connecticut
|
+$2.33M |
| 2 |
DCM
DG Capital Management
New York
|
+$557K |
| 3 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$196K |
| 4 |
BlackRock
New York
|
+$121K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$94.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$766K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$208K |
| 3 |
ACA
Apis Capital Advisors
New York
|
-$163K |
| 4 |
Morgan Stanley
New York
|
-$148K |
| 5 |
Two Sigma Investments
New York
|
-$120K |
FENC Hedge Fund Activity: Q3 2023 in Review
55 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q3 2023, worth a combined $108M — down 14% from $125M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of FENC and 3 opened new positions — a net loss of 1 holder — while 16 trimmed existing stakes and 17 added.
The largest buyer was Solas Capital Management, adding an estimated $2.33M. The largest seller was Millennium Management, exiting entirely with an estimated $766K sold.
- 55 institutional investors held Fennec Pharmaceuticals (FENC) as of Q3 2023, down from 56 in Q2 2023.
- Funds reported $108M of Fennec Pharmaceuticals stock for Q3 2023, down 14% quarter-over-quarter.
- 3 funds opened new Fennec Pharmaceuticals positions in Q3 2023 and 4 closed out, a net change of -1 holder.
- The largest Fennec Pharmaceuticals buyer in Q3 2023 was Solas Capital Management, an estimated $2.33M added.
- The largest Fennec Pharmaceuticals seller in Q3 2023 was Millennium Management, an estimated $766K sold.
Based on aggregated 13F filings for Q3 2023.